CXCL8 and non-small cell lung carcinoma: Based on enzyme-linked immunosorbent assays (ELISA), a recent study profiled the plasma proteomics of NSCLC patients and identified CXCL8 and CXCL10 as biomarker for inferior response to ICI [13].